GlassScriptPhysician profile
Mark Bryan Go Ting
NPI 1588925861
$6,762.61
in general payments reported to CMS, 2019-2025
17 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $581 · 2021: $884 · 2022: $801 · 2023: $715 · 2024: $1,132 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,429.29 |
| Education | $265.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,914.67 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $1,662.82 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $739.51 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Nuedexta |
| Vanda Pharmaceuticals INC. | $426.59 | 2025 | Fanapt |
| Abbvie INC. | $408.55 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $345.89 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $333.41 | 2019-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $271.94 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $162.21 | 2019 | |
| Boston Scientific Corporation | $139.42 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $97.51 | 2025 | |
| Sunovion Pharmaceuticals INC. | $88.90 | 2019-2020 | |
| Allergan, INC. | $57.24 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $41.40 | 2022-2025 | |
| Axsome Therapeutics, INC. | $37.20 | 2022-2025 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.17 | 2022 | |
| Lundbeck LLC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bryan Ting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.